VEGFA and colorectal carcinoma: Furthermore, most clinical trials testing agents targeting the vascular endothelial growth factor (VEGF) pathway in CRC provided evidence for increased progression-free survival but failed to demonstrate a substantial overall survival benefit, suggesting that anti-angiogenic treatment induces a biological adaptation leading to disease modification [9].